Teva Pharmaceuticals’ Dipesh Patel on Building Digital Capabilities in a Trust-First Category

Why It Matters

Regulatory compliance and consumer trust are critical in OTC, making digital speed insufficient without robust safeguards. Companies that master this balance can gain competitive advantage and accelerate market adoption.

Key Takeaways

• AI scales content, but human oversight required
• Trust and regulation limit digital speed in OTC
• Building digital from scratch needs new mindset
• Patel leverages math background for problem solving
• Transition from Unilever to Teva highlights category differences

Pulse Analysis

The OTC pharmaceutical sector sits at the intersection of rapid consumer expectations and stringent regulatory oversight, creating a unique trust‑first environment. Digital leaders must design platforms that not only deliver speed but also embed compliance checks, data provenance, and transparent sourcing. By treating trust as a core product attribute rather than an afterthought, brands can differentiate themselves in a crowded marketplace where misinformation can erode credibility instantly.

Artificial intelligence offers unprecedented scalability for content creation, enabling brands to generate product descriptions, dosage instructions, and compliance statements at volume. However, Patel warns that without robust guardrails—such as automated fact‑checking, version control, and mandatory human review—AI‑generated material can introduce errors that jeopardize patient safety and invite regulatory penalties. The optimal model blends machine efficiency with expert oversight, ensuring that every piece of content meets both brand standards and legal requirements.

Strategically, building digital capabilities from the ground up demands a mindset shift from incremental optimization to foundational architecture. Teams must adopt agile frameworks that accommodate evolving regulations while fostering cross‑functional collaboration between marketing, legal, and IT. Companies that successfully integrate these practices can accelerate time‑to‑market, improve consumer confidence, and capture market share in an industry where trust is the ultimate currency. The future will likely see more pharma firms investing in AI‑enabled, compliance‑centric platforms to stay ahead of both competitors and regulators.